Researchers Find Vitaline CoQ10 Slows Progression of Parkinson's Disease by Close to 45 Percent

-- NIH Fast-Tracks Third-Phase Research --

GREEN BAY, Wis.--(BUSINESS WIRE)--Oct. 14, 2002--The estimated 1.5 million Americans who suffer from Parkinson's Disease have new hope, according to an article published this month in the Archives of Neurology.
Research sponsored by the National Institute of Neurological Disorders and Stroke found 1200 mg. daily of Vitaline CoQ10, a nutritional supplement with three patents pending, slowed the progression of Parkinson's Disease 44 percent.

Vitaline CoQ10 has been the subject of more than 20 research studies, review articles, and abstract presentations. Vitaline CoQ10 is especially attractive because it is safe in high dosages and has been proven to penetrate the cell. It is the only CoQ10 of the hundreds on the market to meet both these criteria.

"These positive results are a sign of hope for those suffering from Parkinson's Disease," said M. Flint Beal, M.D, professor and chairman, Department of Neurology Cornell University Medical College. "Research on CoQ10 must continue so that we may verify and move forward our current understanding of this powerful nutrient, and its role within the human brain."

Parkinson's Disease is a degenerative neurological disorder that is characterized by resting tremors, slowness of movement and muscular rigidity. Parkinson's Disease affects approximately one percent of the population over 65 years of age.

No other treatment has been shown to slow the progression of this deadly disease, which afflicts Pope John Paul III, Muhammad Ali and Michael J. Fox. This month Dutch Prince Claus, husband of Queen Betrix, died after a long battle with Parkinson's Disease.

The National Institutes of Health is fast-tracking the next phase of research to confirm results on a larger pool of participants.

"Clearly the data of the Parkinson Study Group in this article are intriguing and provocative therapeutic findings and offer considerable potential hope for future allied therapies," said Roger Rosenberg, editor of Archives of Neurology, in an editorial.

The study was conducted by the University of California San Diego in association with the Parkinson's Disease Study Group, the Clinical Trials Coordination Center and the Department of Biostatistics at the University of Rochester at 10 research sites across the country.

Researchers studied 80 participants, all in early stages of the disease, over four years using the Unified Parkinson Disease Rating Scale at baseline and months one, four, eight, 12 and 16 to measure success. The greatest reduction in progression was found in the activity of daily living subscores. Researchers also tested lower CoQ10 dosages of 300 mg. and 600 mg. with gradations of benefits.

CoQ10 is a natural fat-soluble nutrient present in virtually every cell in the body. It is found in the mitochondria, where organic molecules are broken down to create energy for cellular functions. Because of its unique role at the cellular level, CoQ10 has been researched for benefits throughout the body.

Aging, nutritional deficiencies and increased tissue demands can all decrease the body's natural CoQ10 production.

This is the second clinical trial in a year to see benefit in using Vitaline CoQ10 to manage the progression of a fatal neurological disease. Last year, researchers at the University of Rochester found the supplement slowed the progression of Huntington's Disease by 20 percent.

Recently, researchers from Harvard Medical School found Vitaline CoQ10 successfully crosses the blood-brain barrier to enter and increase the amount of CoQ10 in the cell mitochondria. Vitaline CoQ10 is unique for this reason, as no other CoQ10 has been proven to do this.

Vitaline CoQ10 has a unique and proprietary formula, delivery mechanism and manufacturing process, for which it has developed multiple patents pending. Other CoQ10-containing products have not been proven safe, tolerable or effective. Many readily available CoQ10-containing products contain ingredients which are harmful at the high doses used in the clinical research.

Vitaline Formulary offers the Vitaline products, as used in the clinical trials, at below wholesale cost. Interested parties may visit or call 1-800-287-5972 for additional information or to order product. Vitaline has donated more than $100,000 to Parkinson's Disease research.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.